Lecturer Biographies

Third International Conference

Radica Vavan

Radica Vavan is a senior advisor for regulation of drug prices at the Ministry of Foreign and Internal Trade and Telecommunications, Republic of Serbia. She has held this position since 2003.
She has a degree in economics. She has participated in proposing several decrees on drug prices in Serbia (about 60 decrees concerning drug pricing); proposed economic policy for drug prices; proposed criteria for setting up and determination of maximum prices for prescription drugs for human use.

In 2011 she worked as a Consultant - Lecturer on the project „Drafting decrees with criteria for setting maximum prices of medicines“ as a part of Consulting Services: „Technical assistance in delivering training, capacity building and skills transfer services to Agency for Medicines and Medical Devices of Montenegro (CALIMS)“.

Dragana Baltezarević, MD, spec

Dragana Baltezarević is currently employed at the Department of drug policy and pharmacoeconomics at the Republic Fund of Health Insurance (RFZO) in Belgrade, Serbia.
She is a medical doctor. Previously working at the pharmaceutical company ‘Hemofarm- STADA’ for more than five years, as a Medical representative, Product (SBU) manager and Medical advisor at the central Portfolio Service and as a consultant/licenced trainer for DRG system: ‘’Serbia Health Project - AF’’ at the Ministry of Health - Republic of Serbia. Meanwhile, she finished her specialization in Pharmacy (pharmacoeconomics, and pharmaceutical legislative).
At the Department of drug policy and pharmacoeconomics at the Republic Fund of Health Insurance, she is responsible for reimbursement List: for pharmaceutical reimbursement strategy, drug application processing, monitoringof drugs consumption.Also, she is a member of the Committee for the therapy of ulcerative colitis and M.Crohn:Humira (adalimumab) & Remicade (infliksimab) as well as of ATC subcommittees.

Dragana Baltezarević is currently employed at the Department of drug policy at the Republic Fund of Health Insurance (RFZO) in Belgrade, Serbia. She is a medical doctor. Previously working at the pharmaceutical company “Hemofarm- STADA” for more than five years, as a Medical representative, Product (SBU) manager and Medical advisor at the central Portfolio Service and as a consultant for the DRG system implementation with the World Bank project “Serbia Health Project – AF”. Meanwhile, she finished her specialization in Pharmacy (pharmacoeconomics and pharmaceutical legislature). As a pricing and reimbursement specialist at the RFZO, she is responsible for analysis of the reimbursement list, pharmaceutical reimbursement strategy and drug application processing, as well as monitoring of drug utilisation. She is a member of the ATC subcommittees: for A, H, M, V ATC groups, then Committees for approving the therapy (List C: 1. adalimumab/infliksimab, 2. gefitinib/erlotinib), central tender Committees for: blood and blood derivates, medical gases, biological therapy and the Committee for Pharmacoeconomics. She also carries out communication between Serbian and other HIFs through the PPRI network.

Bojan Trkulja

Bojan Trkulja, director of the Association of Manufacturers of innovative medicines INOVIA in Belgrade, Serbia from 1st December 2010. He was born in 1971 in Belgrade, where he completed his elementary, high school and medical university. After a successful internship and passing the state exam, he worked in the office of F. Hoffmann - La Roche in Belgrade, from December 1999. Over the last 11 years he held a variety of positions, from associate through the Medical Product Manager, Compliance Officer and Market Access Manager.

Domenik Tomek

Domink Tomek is the current president of ISPOR Chapter Slovakia. He is teaching at the Faculty of Medicine, Slovak Medical University, and Faculty of Pharmacy, Comenius University, Bratislava, Slovakia. He is a founding member of the Slovak Society for Pharmacoeconomics where he pioneered and founded patient empowerment and patient education in Slovakia. Dr Tomek is a former member of the Drug committee of State lnstitute for Drug Control, of the Pricing Committee of Ministry of Finance and of the Reimbursement Committee of Ministry of Health. Dr Tomek has a doctor degree in clinical pharmacy, a PhD in the field of public health and degrees of postgraduate specializations in the management of public pharmacy, preparation of radiopharmaceuticals, revision pharmacy for health insurance, pharmacoeconomics and management of public health.

Martina Bogut

Martina Bogut is an adviser at the Ministry of Health, Republic of Croatia from January 2013. She was born 1981 in Osijek. She was finished Faculty of Economics and additional training in accounting, information technology, human resources, project management and health economics. She is master of economics and currently extra attending specialist postgraduate studies in the field of organizations and management in health care at the Faculty of Economics and at the Faculty of Medicine in Zagreb. Martina Bogut worked in Croatian Institute for Health Insurance from 2003 to 2013. She held a variety of positions, including head of department for drugs and medical products.
Research area is health economics, analytics, pharmacoeconomics and health care management. She is a co-author on the several publications including “Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States”, also she is contributing to the Croatian National Health Strategy 2012.-2020.

Dávid Dankó

Dávid Dankó is research leader at the Institute of Management of the Corvinus University of Budapest, where he teaches pharmaceutical and medical device reimbursement, health care management and strategic management. He is also managing director of Ideas & Solutions, a strategic advisory firm which works together with leading pharmaceutical and medical device manufacturers on making new medicines accessible for patients, as well as local portfolio strategies and patient adherence management.
Dávid received his MSc degree in Economics at Corvinus in 2003, and a PhD degree in 2012 with his thesis on long-term resource management in the pharmaceutical industry. He has been the co-editor of a comprehensive textbook on reimbursement policy.
Between 2003 and 2008, he worked as a consultant specialized in health care and life sciences, working with local and multinational companies as well as the Hungarian government. His consulting and expert assignments were mainly focused on health care reform, strategy formulation and implementation, and business planning. Between 2008 and 2010, he worked on the payer side, as deputy head for the strategy, analysis and integration of the Department of Reimbursement at the Hungarian National Health Insurance Fund Administration. There he was primarily responsible for pharmaceutical and medical device reimbursement strategy, concept development, international co-operations, and the co-ordination of IT development as well as research and analysis activities.
Dávid Dankó is a lecturer at Vienna School of Clinical Research, Université Lyon 1 (EMAUD), Semmelweis University of Budapest, Eötvös Lorand University, and he a regular speaker at international workshops and conferences on pharmaceutical and medical device reimbursement.

Magdalena Wladysiuk

Magdalena Wladysiuk is a president and owner of HTA Consulting. She is the president of the Central & Eastern European Society of Technology Assessment in Health Care (CEESTACH). She is a medical doctor with MBA in Technology Management. She is one of the authors of 100 HTA reports for industry and public health insurance and financial analyses developed since 2001 (some are in Polish and some are available in English and can be found on www.hta.pl/raports). From 2006 till 2008 she provided consultancy services for the Serbian Ministry of Health in respect to evidence based basic benefit package, design and feasibility study on different models of HTA Agency in Serbia and quality of best practice guidelines. In addition she was also involved in the Evidence Based Heath care (EBHC) development, HTA systemic implementation, in-depth training of Serbian HTA analysts and development of 3 country specific HTA reports. Currently she closely works with MoH Poland counterparts and private sector, develops strategic planning, economic analysis, health promotion, standards, cost reduction and clinical/ health information systems.
Magdalena Wladysiuk is involved in promotion of HTA in the region of CEE which resulted in international cooperation in education and HTA. She organized many national and international HTA workshops and conferences and she was a speaker at most of them.

Alan Haycox

Dr Alan Haycox is a Reader in Health Economics at the University of Liverpool Management School, UK. He completed his education with a BA in Economics, and later obtained a MA in Regional Economics and a PhD in Health Economics at the University of Lancaster, UK. Within the Management School, Dr Haycox is the Director of Liverpool Health Economics (LHE). LHE aims to improve the quality and cost-effectiveness of prescribing by working in collaboration with health services and the pharmaceutical industry to inform and support health policy decision-making. Under his leadership, LHE has gained an international reputation as a leader in the field of pharmacoeconomics research.
Dr Haycox has extensive experience and expertise in health economic evaluations in a broad spectrum of disease groups and interventions. In addition to publishing over 100 peer reviewed papers in journals such as the BMJ and Pharmacoeconomics, Dr Haycox has authored a large number of Health Technology Assessment Monographs.
Dr Haycox is a member of the College of Experts who referee proposals submitted to the HTA Programme in the UK. He is also an expert advisor to the National Prescribing Centre (NPC) in England and the Scottish Medicines Consortium (SMC) in Scotland in addition to a wide range of national and international regulatory and funding authorities. He is a member of the NICE Technology Appraisal Committee which decides on the introduction of new drugs into the British National Health Service.

Krzysztof Landa

Krzysztof Landa is the CEO of HTA Audit, a company dealing with quality of HTA reports directed to authorities and public institutions in Poland and the President of Watch Health Care Foundation (www. WatchHealthCare.eu). From 2010 till 2011 he was President of the Central & Eastern European Society of Technology Assessment in Health Care (www.CEESTAHC.org). In 2006-2007 Dr Landa was the Director of Drug Policy Department in the Central Office of National Health Fund. In 2004 Krzysztof Landa was elected to the Board of Directors of Health Technology Assessment International (HTAi) and performed his duties till mid 2007. He was the Chairman of the LOC of the first HTAi Annual Meeting 2004, held in Krakow, Poland. Dr Landa is a graduate of the University School of Medicine and received his management education at the Postgraduate School of Public Health of Jagiellonian University in Krakow. Promotion of HTA in the region of CEE resulted in international cooperation in education and HTA. Dr Landa organized many national and international HTA workshops and conferences. In years 2006 – 2008 Dr Landa provided consultancy for the Serbian Ministry of Health. He was team leader of the World Bank project aimed at introduction of HTA in Serbia, implementation of EBHC principles to the management of basic benefit package and designing a governmental HTA Agency.

Mark Parker

Mark Parker is Senior Economic modeller for the University of Liverpool Health Economic Unit, Liverpool Cancer Trials Unit and Technical director of Evaluate Econ Ltd, UK. Early background was in software and electronic engineering (University of Manchester) and real time Digital Signal Processing, along with RF design. Completed the MSc in Health Economics at the University of York, UK (2009). Currently PhD submission pending in Health Economic Modelling at the University of Liverpool. These roles have mostly involved developing models and evidence based messages for a wide range of disease areas for global value dossiers and HTA submissions to NICE, SMC and CVZ, along with internal decision-making. Working with GSK (vaccines), Sanofi Aventis (Diabetes), Wirral Primary Care Trust (Real world data validation), CHAMPS (weight management interventions) and Shire (biological in a chronic condition). Experience in a vast range of disease areas and population modelling, with a strong educational background in economics, software development, distributed systems and computation, Artificial Intelligence (1st, BSc Economics and Computer Science, UoL). Applying these skills to develop evidence based value arguments for Health Technology Assessment. This training, education and experience provide the means to apply the world’s most advanced techniques to solve complex problems in a methodical, transparent and comprehensible way, with a core focus on knowledge transfer. Enjoys a wide range of water, snow and motor sports.
Sesija SFE SFUS - VII Kongres farmaceuta Srbije
Petak 12.10. 2018./ Hotel Crowne Plaza , Beograd, Srbija
Preliminarni program

VI međunarodna SFE SFUS konferencija
2. jun 2017. godine, Beograd, hotel Metropol, Srbija.

Sekcija za farmakoekonomiju Saveza farmaceutskih udruženja Srbije (SFE SFUS) organizuje Šestu međunarodnu konferenciju sa temom:

Peta međunarodna konferencija - Predavači
9. i 10. oktobar 2015. godine Beograd, hotel Metropol
dr sc. Brian Godman, Institut za farmaciju i biomedicinske nauke Strathclyde, Glazgov, Velika Britanija, Karolinska Institut, Švedska

dr sc. Wija Oortwijn, partner, ECORYS NL Roterdam, Holandija

dr Krzysztof Landa, predsednik, MedInvest Scanner Ltd M.I.S, Poljska

mr sc. Mark Parker, Odsek za zdravstvenu ekonomiju, Fakultet za menadžment, Univerzitet u Liverpulu, Velika Britanija

mr sc. Angela Yu, istraživač Fakulteta za ekonomiju i političke nauke u Londonu, Velika Britanija

Timothy Johnston, lider programa za rast i ljudski razvoj, Jugoistočna Evropa, Evropa i centralna Azija, Svetska banka

dr sc. Dávid Dankó, direktor, Ideas & Solutions, Mađarska

dr Günter Harms, direktor za pristup tržištu i odnose sa javnošcu, Shire, Nemačka

mr sc. Vanesa Benković, konsultant za procenu zdravstvenih tehnologija i istraživanja u zdravstvu, Hrvatska

dr Bojan Trkulja, direktor, INOVIA, Srbija

mr sc. Tanja Novaković, predsednica Sekcije za farmakoekonomiju SFUS, Srbija

mr sc. Jovan Mihajlović, Institut za farmakoepidemiologiju i farmakoekonomiju, Odsek za farmaciju Univerziteta u Groningenu, Holandija

Livio Garattini, Mario Negri Institute, Milano, Italija

Jakub Adamski, Arcana Institut, Poljska

Alan Haycox, Odsek za zdravstvenu ekonomiju, Fakultet za menažment, Univerzitet u Liverpulu, Velika Britanija

Norbert Wilk, Arcana Institut, Poljska

Neven Lovrinov, Terimanl d.o.o., Hrvatska

Beograd, 28. april 2015. godina, hotel Crowne Plaza
Sekcija za farmakoekonomiju Saveza farmaceutskih Udruženja Srbije
Ciljevi konferencije su:
· Upoznavanje sa specifičnostima biofarmacetskih lekova i biosimilara,

· razumevanje regulative biofarmaceutskih i biološki sličnih lekova,

· predstavljanje kliničkog iskustva sa biološkim lekovima i uopšte,

· razmena iskustava i znanja sa stručnjacima iz regiona I Evrope.
Regulisano uvođenje novih lekova
11-13, maj 2015. godina, Varšava, Pojska
PIPERSKA grupa i Agency za HTA & Tarifni Sistem u Poljskoj i Svetska ždravstvena organižacija, Evropa
Kurs je prvenstveno namenjen zdravstenim stručnjacima koji se bave unapređenjem racionalnom upotrebom lekova posebno novih lekova.
Peti jadranski i Četvrti hrvatski kongres farmakoekonomike i istraživanja ishoda liječenja
Šibenik, Hrvatske, 23. do 26. april 2015. godine
Sekcija za farmakoekonomiku i istraživanje ishoda liječenja Hrvatskog društva za kliničku farmakologiju i terapiju Hrvatskog liječničkog zbora
Teme koje će na predstojećem kongresu biti u posebnom fokusu su: 'Uloga i značaj farmaceutske industrije na cjelokupno gospodarstvo država u regiji' te 'Potreba adaptacije modela za procjenu zdravstvenih tehnologija u državama s visokim rizikom održivosti financiranja zdravstvenih sustava u svrhu očuvanja transparentnosti i konkurentnosti'.
Registri pacijenata u cilju poboljšanja kvaliteta zdravstvene zaštite i smanjenja troškova lečenja
5. februara 2015. godine, hotel Crowne Plaza, Beogradu u 13.00 h
Sekcije za farmakoekonomiju Saveza farmaceutskih Udruženja Srbije (SFUS)
Ciljevi konferencije su:
• Upoznavanje i predstavljanje značaja i vrednosti registara pacijenata
• Upoznavanje sa zdravstenim ishodima terapija i ishodima prijavljenim od strane pacijenata
• Razmena iskustava sa zemljama koje imaju iskustva sa primenom registara pacijenata u
korišćenju podataka za farmakoekonomske analize
• Upoznavanje sa primerima specijalnih ugovora (Risk sharing, Pay per Performance)
Procena zdravstvenih tehnologija za obezbeđenje kvaliteta zdravstvene zaštite
15-16. decembar 2014.,Krakov, Poljska
IX Međunarodni Simpozijum CEESTAHC